Quarterly report pursuant to Section 13 or 15(d)

SUBSEQUENT EVENTS

v3.21.2
SUBSEQUENT EVENTS
3 Months Ended
Jul. 31, 2021
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

 

14. SUBSEQUENT EVENTS

 

The Company contracted Altasciences to conduct a six-month Phase I relative bioavailability study for AL001 for dementia related to Alzheimer’s disease that started on September 10, 2021. The Phase I first-in-human study is for the purpose of determining potential clinically safe and appropriate dosing for AL001 in future studies. AL001 is a lithium-delivering ionic cocrystal under development as an oral treatment for patients with dementia related to mild, moderate and severe cognitive impairment associated with Alzheimer’s disease.